Longitudinal Serum and Cerebrospinal Fluid S100B Concentrations After Aneurysmal Subarachnoid Hemorrhage: An Exploratory Comparison of Historical Cohorts With and Without Cerebrolysin Exposure
- 1Clinical Department of Anesthesiology and Intensive Therapy, Faculty of Medicine, Wroclaw Medical University, 50-367 Wroclaw, Poland
- 2Clinical Department of Anesthesiology and Intensive Therapy, University Clinical Hospital in Wroclaw, 50-556 Wroclaw, Poland
Abstract
Background/Objectives: Cerebrolysin (CBL) has been proposed to exert neuroprotective and neurotrophic effects, but its biological effects after aneurysmal subarachnoid hemorrhage (aSAH) remain uncertain. We investigated longitudinal serum and cerebrospinal fluid (CSF) S100 calcium-binding protein B (S100B) profiles according to CBL exposure. Methods: This retrospective, single-center exploratory cohort study included 67 patients with aSAH (CBL, n = 26; non-CBL, n = 41). S100B was measured in serum and, when CSF access was clinically available, in CSF on days 1, 3, 5, 7, and 10. In the CBL cohort, treatment was initiated before the first study sample, which was obtained approximately 12 h after the first dose on average. Accordingly, day 1 was considered an early post-exposure measurement rather than a pre-treatment baseline. Longitudinal serum and CSF S100B concentrations were analyzed using linear mixed-effects models with patient-specific random intercepts, including CBL exposure, study day, and their interaction. A sensitivity analysis was performed after exclusion of day 1. Results: A significant overall between-cohort difference in serum S100B was observed across the study period (geometric mean ratio [GMR] 0.028, 95% CI 0.013–0.057; p < 0.001), with no significant CBL-by-day interaction (p = 0.218). The association persisted after exclusion of day 1 (GMR 0.023, 95% CI 0.011–0.049; p < 0.001). No significant overall between-cohort difference was observed for CSF S100B (GMR 0.542, 95% CI 0.185–1.584; p = 0.263). The CSF-to-serum ratio was higher in the CBL cohort on days 1, 3, 5, and 7 but not on day 10. No significant between-group differences were observed in delayed cerebral ischemia (DCI), TCD-detected cerebral vasospasm, mortality, or functional outcomes. Conclusions: CBL exposure was associated with persistently lower serum S100B concentrations, whereas no corresponding overall between-cohort difference was observed in CSF. These findings indicate a differential association of CBL exposure with serum and CSF S100B profiles; however, because CBL exposure was completely confounded by treatment era, the observed associations cannot establish a causal treatment effect. Prospective, contemporaneous controlled studies are required to determine whether CBL directly influences S100B dynamics after aSAH.
Related
- Clazosentan, Endothelin-A Receptor Antagonist, Suppresses Interleukin-6 Expression in Cerebrospinal Fluid after Subarachnoid Hemorrhage
- Cerebrospinal fluid hemolysis precedes secondary brain injury after aneurysmal subarachnoid hemorrhage
- Simultaneous determination of osimertinib and almonertinib concentrations in human plasma and cerebrospinal fluid using UPLC-MS/MS method and its clinical applications
- Explainable machine learning–based prediction of postoperative pulmonary infection after aneurysmal subarachnoid hemorrhage clipping and exploratory analysis of enteral nutrition timing: a dual-cohort retrospective study
- Elevation in Plasma p-tau217 Concentrations Among Blood Donors: An Exploratory Cross-Sectional Study
BibTeX
@article{burzynska2026longitudinal,
title = {{Longitudinal Serum and Cerebrospinal Fluid S100B Concentrations After Aneurysmal Subarachnoid Hemorrhage: An Exploratory Comparison of Historical Cohorts With and Without Cerebrolysin Exposure}},
author = {Małgorzata Burzyńska and Adrianna Lebiedzińska and Jarosław Kędziora and Barbara Dragan and Bogusława Lechowicz-Głogowska and Barbara Adamik and Marek Wełna and Waldemar Goździk},
journal = {Journal of Clinical Medicine},
year = {2026},
month = nov,
doi = {10.3390/jcm15218734},
url = {https://www.mdpi.com/2077-0383/15/21/8734},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Longitudinal Serum and Cerebrospinal Fluid S100B Concentrations After Aneurysmal Subarachnoid Hemorrhage: An Exploratory Comparison of Historical Cohorts With and Without Cerebrolysin Exposure
AU - Małgorzata Burzyńska
AU - Adrianna Lebiedzińska
AU - Jarosław Kędziora
AU - Barbara Dragan
AU - Bogusława Lechowicz-Głogowska
AU - Barbara Adamik
AU - Marek Wełna
AU - Waldemar Goździk
PY - 2026
DA - 2026/11/09
JO - Journal of Clinical Medicine
DO - 10.3390/jcm15218734
UR - https://www.mdpi.com/2077-0383/15/21/8734
AB - Background/Objectives: Cerebrolysin (CBL) has been proposed to exert neuroprotective and neurotrophic effects, but its biological effects after aneurysmal subarachnoid hemorrhage (aSAH) remain uncertain. We investigated longitudinal serum and cerebrospinal fluid (CSF) S100 calcium-binding protein B (S100B) profiles according to CBL exposure. Methods: This retrospective, single-center exploratory cohort study included 67 patients with aSAH (CBL, n = 26; non-CBL, n = 41). S100B was measured in serum and, when CSF access was clinically available, in CSF on days 1, 3, 5, 7, and 10. In the CBL cohort, treatment was initiated before the first study sample, which was obtained approximately 12 h after the first dose on average. Accordingly, day 1 was considered an early post-exposure measurement rather than a pre-treatment baseline. Longitudinal serum and CSF S100B concentrations were analyzed using linear mixed-effects models with patient-specific random intercepts, including CBL exposure, study day, and their interaction. A sensitivity analysis was performed after exclusion of day 1. Results: A significant overall between-cohort difference in serum S100B was observed across the study period (geometric mean ratio [GMR] 0.028, 95% CI 0.013–0.057; p < 0.001), with no significant CBL-by-day interaction (p = 0.218). The association persisted after exclusion of day 1 (GMR 0.023, 95% CI 0.011–0.049; p < 0.001). No significant overall between-cohort difference was observed for CSF S100B (GMR 0.542, 95% CI 0.185–1.584; p = 0.263). The CSF-to-serum ratio was higher in the CBL cohort on days 1, 3, 5, and 7 but not on day 10. No significant between-group differences were observed in delayed cerebral ischemia (DCI), TCD-detected cerebral vasospasm, mortality, or functional outcomes. Conclusions: CBL exposure was associated with persistently lower serum S100B concentrations, whereas no corresponding overall between-cohort difference was observed in CSF. These findings indicate a differential association of CBL exposure with serum and CSF S100B profiles; however, because CBL exposure was completely confounded by treatment era, the observed associations cannot establish a causal treatment effect. Prospective, contemporaneous controlled studies are required to determine whether CBL directly influences S100B dynamics after aSAH.
SN - 2077-0383
ER -